Skip to main content
SpringerLink
Log in

Association between MPO 463G>A polymorphism and risk of lung cancer: a meta-analysis

  • Research Article
  • Published:
Tumor Biology

Abstract

There is a possible association between myeloperoxidase (MPO) 463G>A polymorphism and risk of lung cancer, but previous studies report conflicting results. We performed a meta-analysis of available molecular epidemiologic studies to comprehensively assess the association between MPO 463G>A polymorphism and risk of lung cancer. A systemic literature search was performed in Pubmed, Embase, and Wanfang databases for molecular epidemiologic studies on the association MPO 463G>A polymorphism and risk of lung cancer on March 16, 2013. The pooled odds ratios (ORs) with their 95 % confidence interval (95 % CI) were calculated to assess the strength of the association. Twenty-six individual case–control studies with a total of 18,433 subjects (7,752 cases and 10,681 controls) were finally included into the meta-analysis. Overall, MPO 463G>A polymorphism was significantly associated with decreased risk of lung cancer under two main genetic comparison models (for A versus G, OR = 0.91, 95 % CI 0.83–0.99, P = 0.035; for AG/AA versus GG, OR = 0.90, 95 % CI 0.81–0.99, P = 0.029). Meta-analysis of studies with high quality also showed that MPO 463G>A polymorphism was significantly associated with decreased risk of lung cancer under two main genetic comparison models (for A versus G, OR = 0.91, 95 % CI 0.83–0.99, P = 0.035; for AG/AA versus GG, OR = 0.90, 95 % CI 0.80–0.99, P = 0.048). Subgroup analysis by ethnicity further showed that there was a significant association between MPO 463G>A polymorphism and decreased risk of lung cancer in Caucasians but not in Asians. The meta-analysis suggests that MPO 463G>A polymorphism is associated with decreased risk of lung cancer, especially in Caucasians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.

    Article  PubMed  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  4. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.

    Article  PubMed  CAS  Google Scholar 

  5. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.

    Article  PubMed  CAS  Google Scholar 

  6. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55:1462–70.

    Article  PubMed  CAS  Google Scholar 

  7. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23:447–54.

    Article  PubMed  CAS  Google Scholar 

  8. Yuzhalin AE, Kutikhin AG. Common genetic variants in the myeloperoxidase and paraoxonase genes and the related cancer risk: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30:287–322.

    Article  PubMed  CAS  Google Scholar 

  9. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant–463a of the myeloperoxidase gene. Cancer Res. 2000;60:644–9.

    PubMed  CAS  Google Scholar 

  10. Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, et al. Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk. Cancer Res. 2004;64:7634–9.

    Article  PubMed  CAS  Google Scholar 

  11. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001–3.

    PubMed  CAS  Google Scholar 

  12. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463g– > a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181–4.

    PubMed  Google Scholar 

  13. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, et al. Point: Myeloperoxidase -463g –> a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1550–4.

    PubMed  CAS  Google Scholar 

  14. Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not gstm1 is associated with risk of lung squamous cell carcinoma in a chinese population. Int J Cancer. 2002;102:275–9.

    Article  PubMed  CAS  Google Scholar 

  15. Schabath MB, Spitz MR, Delclos GL, Gunn GB, Whitehead LW, Wu X. Association between asbestos exposure, cigarette smoking, myeloperoxidase (mpo) genotypes, and lung cancer risk. Am J Ind Med. 2002;42:29–37.

    Article  PubMed  CAS  Google Scholar 

  16. Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, et al. Counterpoint: The myeloperoxidase -463g–> a polymorphism does not decrease lung cancer susceptibility in caucasians. Cancer Epidemiol Biomarkers Prev. 2002;11:1555–9.

    PubMed  CAS  Google Scholar 

  17. Cajas-Salazar N, Sierra-Torres CH, Salama SA, Zwischenberger JB, Au WW. Combined effect of mpo, gstm1 and gstt1 polymorphisms on chromosome aberrations and lung cancer risk. Int J Hyg Environ Health. 2003;206:473–83.

    Article  PubMed  CAS  Google Scholar 

  18. Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, Laurent-Puig P, et al. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics. 2003;13:729–39.

    Article  PubMed  CAS  Google Scholar 

  19. Wu XM, Zhou YK, Ren S, Hao QL. Gene polymorphism of myeloperoxidase and genetic susceptibility to lung cancer. Ai Zheng. 2003;22:912–5.

    PubMed  CAS  Google Scholar 

  20. Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.

    Article  PubMed  CAS  Google Scholar 

  21. Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the gstm1, gstp1, mpo, xrcc1, and nqo1 genes in chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the cdkn2a and rarb genes. Cancer Genet Cytogenet. 2005;162:10–20.

    Article  PubMed  CAS  Google Scholar 

  22. Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM. Cyp1a1 ile462val and mpo g-463a interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis. 2006;27:525–32.

    Article  PubMed  CAS  Google Scholar 

  23. Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase -463g > a polymorphism and risk of primary lung cancer in a korean population. Cancer Detect Prev. 2006;30:257–61.

    Article  PubMed  CAS  Google Scholar 

  24. Zhang T, Hong X, Wu Y. Myeloperoxidase polymorphism in lung cancer patients of henan han population. J Zhengzhou Univ (Med Sci). 2006;42:448–50.

    Google Scholar 

  25. Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase g-463a polymorphism and risk of lung and prostate cancer in a turkish population. Mol Med Rep. 2011;4:87–92.

    PubMed  CAS  Google Scholar 

  26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed  Google Scholar 

  27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    PubMed  CAS  Google Scholar 

  28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  PubMed  CAS  Google Scholar 

  29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  PubMed  CAS  Google Scholar 

  30. Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163–6.

    Article  PubMed  CAS  Google Scholar 

  31. Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, et al. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in finland. Cancer Lett. 2001;164:161–7.

    Article  PubMed  CAS  Google Scholar 

  32. Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, et al. Myeloperoxidase (mpo) genotype and lung cancer histologic types: the mpo −463 a allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002;102:530–5.

    Article  PubMed  CAS  Google Scholar 

  33. Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, et al. Myeloperoxidase −463 (g– > a) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc. 2002;77:17–22.

    Article  PubMed  CAS  Google Scholar 

  34. Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, et al. Mpo and sod2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004;214:69–79.

    Article  PubMed  CAS  Google Scholar 

  35. Yang M, Choi Y, Hwangbo B, Lee JS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer. 2007;57:135–42.

    Article  PubMed  Google Scholar 

  36. Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. Cyp1b1, cyp1a1, mpo, and gstp1 polymorphisms and lung cancer risk in never-smoking korean women. Lung Cancer. 2008;60:40–6.

    Article  PubMed  Google Scholar 

  37. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–9.

    Article  PubMed  CAS  Google Scholar 

  38. Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mrna expression. PLoS One. 2009;4:e5652.

    Article  PubMed  Google Scholar 

  39. Pabalan N, Jarjanazi H, Sung L, Li H, Ozcelik H. Menopausal status modifies breast cancer risk associated with the myeloperoxidase (mpo) g463a polymorphism in caucasian women: a meta-analysis. PLoS One. 2012;7:e32389.

    Article  PubMed  CAS  Google Scholar 

  40. Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, et al. Myeloperoxidase g-463a polymorphism and lung cancer: a huge genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. 2007;9:67–73.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. State Key Laboratory of Respiratory Disease, Department of Medicine, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, 510120, China

    Chengzhi Zhou, Qun Luo, Yinyin Qing, Xinqing Lin, Yangqin Zhan & Ming Ouyang

Authors
  1. Chengzhi Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qun Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yinyin Qing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinqing Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yangqin Zhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming Ouyang.

Additional information

Chengzhi Zhou and Qun Lou contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, C., Luo, Q., Qing, Y. et al. Association between MPO 463G>A polymorphism and risk of lung cancer: a meta-analysis. Tumor Biol. 34, 3449–3455 (2013). https://doi.org/10.1007/s13277-013-0921-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0921-x

Keywords

Search

Navigation